The choice of radiopharmaceutical is dependent on the tumour type. Currently we provide a service for:
- patients with neuroendocrine tumours receiving Y90-Dotatate
- metastatic castration resistant prostate cancer receiving bone palliation therapy (Radium-223, Strontium-89)
- Thyroid cancer and benign thyroid disease receiving Radioiodine treatment
The therapeutic radiopharmaceutical is manufactured either in The Royal Marsden Radiopharmacy Department or off-site in a commercial Radiopharmacy.
For some therapies patients are treated as outpatients and can leave the hospital as soon as the therapy has been administered. However, other patients will need to be admitted to a dedicated, appropriately shielded rooms as they will need to remain in hospital until the amount of radiation inside them has reduced to a required level.